DOCK2 and liver cancer: Then, univariate Cox analysis and multivariate Cox analysis were performed based on the age, gender, clinical stage, tumor stage, and risk score of DOCK2 mutant liver cancer patients, thus building a clinical prediction model, the efficacy of which in 28 DOCK2 mutant samples was 85.8% (Figure 4G).